How CGRP Monoclonal Antibodies Work for Migraine

Understanding how do CGRP antibodies work migraine prevention requires a quick look at the biology behind a migraine attack itself. Once you know what CGRP does in the nervous system, the mechanism of these therapies becomes straightforward. This article explains the science clearly, without jargon where it can be avoided.

What CGRP Is and Why It Matters in Migraine

CGRP stands for calcitonin gene-related peptide. It is a small protein that acts as a signaling molecule in the nervous system and is found throughout the body, including in blood vessels and pain-sensing nerves. During a migraine, CGRP levels in the blood rise significantly. When researchers infused CGRP into people with a history of migraine, it reliably triggered attacks. That cause-and-effect relationship is what made CGRP a credible therapeutic target.

For a deeper primer on the molecule itself, see What is CGRP and the more detailed breakdown in Calcitonin Gene-Related Peptide Explained.

CGRP's main roles relevant to migraine are:

• Vasodilation: CGRP causes blood vessels to dilate. The dilation of cranial blood vessels is thought to contribute to the throbbing pain characteristic of migraine.
• Pain amplification: CGRP is released from trigeminal nerve fibers and sensitizes pain pathways, making the nervous system more reactive.
• Neurogenic inflammation: Elevated CGRP promotes inflammation around the meninges (the membranes surrounding the brain), which contributes to the headache phase.

How CGRP Monoclonal Antibodies Work for Migraine Prevention

A monoclonal antibody is a lab-engineered protein designed to bind to one specific target with high precision. In the case of CGRP-targeting therapies, these antibodies are built to intercept the CGRP signaling pathway before it can trigger the pain cascade.

There are two distinct approaches used by CGRP antibodies:

Both approaches accomplish the same functional goal: reducing CGRP's ability to trigger vasodilation and pain sensitization in the trigeminal system. Neither approach eliminates CGRP entirely. The aim is to reduce CGRP activity to a level that prevents migraine without disrupting the molecule's other normal physiological functions.

Why These Are Preventive Medications

Because monoclonal antibodies are proteins, they cannot survive the digestive process like a pill can. They are administered by injection, either subcutaneously (under the skin) or intravenously. Once in the bloodstream, they remain active for weeks, which is why CGRP antibodies are dosed monthly or quarterly rather than taken daily. This long duration makes them practical as preventive agents rather than acute treatments.

This is a meaningful distinction. A preventive medication works in the background over time, gradually reducing attack frequency. It is not designed to stop an attack in progress. Patients typically continue to use a separate acute medication for attacks that do occur.

Only your clinician can determine whether a CGRP-targeting therapy is appropriate for you, adjust your dose, or decide when to start or stop treatment. Do not make changes to your medication regimen without consulting them.

Who Is Typically Considered for CGRP Preventive Therapy

CGRP-targeting therapies are generally considered for people with migraine who have a significant attack burden and have not achieved adequate results with other preventive options. Clinical trials enrolled both people with episodic migraine and chronic migraine. Chronic migraine is defined as 15 or more headache days per month for more than 3 months, with at least 8 of those days meeting migraine criteria.

Typical candidacy factors that clinicians and insurers consider include:

• A confirmed diagnosis of migraine
• A meaningful frequency of attacks that affects daily functioning
• Prior trials of at least two or three standard preventive medications without adequate benefit
• No contraindications to the specific therapy

The prior authorization process for these medications is specifically designed to document these factors. If you are working through that process, see CGRP Prior Authorization and Renewal for a detailed walkthrough of what insurers typically require.

What to Track to Measure Whether the Therapy Is Working

Because CGRP antibodies reduce attack frequency over time rather than eliminating migraines immediately, tracking is essential. Without a documented baseline, it is nearly impossible to demonstrate improvement, either to yourself or to an insurer reviewing a renewal.

The most important metrics to log:

• Monthly migraine days: The primary outcome measure used in clinical trials and in most prior authorization renewals.
• Monthly headache days: Some insurance plans look at total headache days, not just days meeting full migraine criteria.
• Acute medication use: Tracking how often you reach for a rescue medication shows functional improvement beyond headache frequency.
• Attack severity: A reduction in average severity counts as a meaningful response even if frequency changes slowly.
• Disability scores: Instruments like MIDAS and HIT-6 translate your migraine burden into standardized scores that clinicians and insurers recognize.

The Migraine Reduction Calculator can help you see whether your recent months show a meaningful percentage reduction from your pre-treatment baseline. If you are not sure whether your pattern qualifies as episodic or chronic, the Chronic or Episodic Migraine tool can clarify the distinction.

For a fuller picture of how to interpret your tracking data over time, see Measuring CGRP Progress.

The Relationship Between Mechanism and Response Time

One of the most common points of confusion with CGRP antibodies is response timing. Because these are not acute medications, some people expect immediate relief and become discouraged when the first month shows only modest improvement.

The mechanism explains why patience is warranted. The antibody must accumulate to steady-state levels in the body. The sensitized trigeminal pain pathways, which have often been in a heightened state for years in people with frequent migraine, do not normalize overnight. Most clinical trial protocols evaluated outcomes at three months, not one month, for this reason.

Some people do see dramatic improvement in the first month. Others find that meaningful reduction takes two to three months to emerge. A small proportion find that a particular CGRP therapy does not work for them at all, which is also a valid clinical outcome, not a failure of the patient.

Logging every month matters regardless of how quickly you respond, because that longitudinal record is what demonstrates your trajectory over time.

Putting the Science to Work

Knowing how CGRP antibodies interact with your nervous system is useful context, but the practical benefit comes from combining that knowledge with consistent tracking. Every month you log, your app builds the before-and-after picture that your clinician needs for renewal documentation and that your insurer requires to confirm the therapy is producing measurable benefit. If a treatment change ever becomes necessary, that logged history gives your clinician something concrete to work from. As always, consult your doctor before making any changes to your treatment plan.